SCHEMBL1548784

SCHEMBL1548784

O=C(Nc1ccc(C(F)(F)F)cc1)c1cccc2c1OCCN2c1ncccc1Cl

nearest known ligand 0.53

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
TRPV1 Q8NER1 10/20 0.49
MEN1 O00255 1/20 0.46
KMT2A Q03164 1/20 0.46
PTGES O14684 2/20 0.45
KDM4E B2RXH2 2/20 0.43
ALDH1A1 P00352 1/20 0.43
LMNA P02545 1/20 0.43
MAPT P10636 1/20 0.43
HTT P42858 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
GAA P10253 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14541031 0.96 TRPV1 (0.49) TRPV1MEN1KMT2APTGESKDM4E
SCHEMBL2348373 0.91 KMT2A (0.58) MEN1KMT2APTGESKDM4EALDH1A1
SCHEMBL1548848 0.91 TRPV1 (0.56) TRPV1ALDH1A1MAPTNPSR1GAA
SCHEMBL2346536 0.90 TRPV1 (0.49) TRPV1ALDH1A1SMN1; SMN2
SCHEMBL2348103 0.90 ALDH1A1 (0.53) TRPV1MEN1KMT2AALDH1A1MAPT
SCHEMBL2346049 0.90 TRPV1 (0.52) TRPV1MEN1KMT2AALDH1A1MAPT
SCHEMBL2342206 0.89 GRM4 (0.50) TRPV1MEN1KMT2APTGESALDH1A1
SCHEMBL1549504 0.89 TRPV1 (0.50) TRPV1MEN1KMT2APTGESALDH1A1
SCHEMBL2344009 0.89 TRPV1 (0.47) TRPV1MEN1KMT2APTGES
SCHEMBL2349154 0.89 P2RY1 (0.47) TRPV1KMT2AMAPTHTTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2314585-B1 Condensed benzamide compounds as inhibitors of vanilloid receptor subtype 1 (VR1) activity JAPAN TOBACCO INC (JP) 2012-09-12 EP claimed
US-20060035882-A1 CONDENSED BENZAMIDE COMPOUNDS AND INHIBITORS OF VANILLOID RECEPTOR SUBTYPE 1 (VR1) ACTIVITY JAPAN TOBACCO INC. (JP) 2006-02-16 US claimed
US-8008292-B2 Condensed benzamide compounds and inhibitors of vanilloid receptor subtype 1 (VR1) activity JAPAN TOBACCO INC. (JP) 2011-08-30 US disclosed
US-8008292-B2 Condensed benzamide compounds and inhibitors of vanilloid receptor subtype 1 (VR1) activity JAPAN TOBACCO INC. (JP) 2011-08-30 US disclosed
US-8008292-B2 Condensed benzamide compounds and inhibitors of vanilloid receptor subtype 1 (VR1) activity JAPAN TOBACCO INC. (JP) 2011-08-30 US disclosed
EP-2314585-A1 Condensed benzamide compounds as inhibitors of vanilloid receptor subtype 1 (VR1) activity Japan Tobacco, Inc. (JP) 2011-04-27 EP disclosed
EP-1777225-A1 FUSED BENZAMIDE COMPOUND AND VANILLOID RECEPTOR 1 (VR1) ACTIVITY INHIBITOR Japan Tobacco, Inc. (JP) 2007-04-25 EP disclosed
US-20060035882-A1 CONDENSED BENZAMIDE COMPOUNDS AND INHIBITORS OF VANILLOID RECEPTOR SUBTYPE 1 (VR1) ACTIVITY JAPAN TOBACCO INC. (JP) 2006-02-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060035882-A1 CONDENSED BENZAMIDE COMPOUNDS AND INHIBITORS OF VANILLOID RECEPTOR SUBTYPE 1 (VR1) ACTIVITY TRPV1, TRPV2, TRPA1 TRPV1 1/4885MEN1 2454/4885KMT2A 1071/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.